Three posters on the multi-AbKine platform presented concurrently at AACR 2026 in the U.S.
[by Ji, Yong Jun] Y-Biologics announced on January 7 that it has entered into a contract development and manufacturing organization (CDMO) agreement with WuXi XDC of China to develop a novel drug pipeline based on its proprietary next-generation triple-target immuno-oncology platform, ‘Multi-AbKine.’
Y-바카라 has chosen WuXi XDC, a CDMO with world-class capabilities in the development and mass production of complex multi-antibody therapeutics, including bispecific and trispecific antibodies. According to the Korea Biotechnology Industry Organization (KoreaBio), WuXi XDC ranked second in global CDMO market share as of 2024, following Switzerland-based Lonza.
Under the agreement with WuXi XDC, overall chemistry, manufacturing, and controls (CMC) development will be conducted for ‘AR170 (PD-1 x VEGF x IL2v),’ a bispecific antibody-cytokine fusion candidate, together with the provision of the data package required for submission of an Investigational New Drug (IND) application in the U.S. In parallel, for the second dual antibody-cytokine fusion candidate, ‘AR166,’ the agreement encompasses the development of a research cell bank (RCB) for mass production.
The Multi-AbKine platform, which aims to become a potential alternative to MSD's (Merck, USA) PD-1 inhibitor Keytruda, a global immuno-oncology blockbuster with annual sales exceeding KRW 40 trillion (approximately USD 27.6 billion), is developing three pipeline programs simultaneously. Among these candidates, ‘AR170’ and ‘AR166’ are progressing toward IND submissions for global clinical trials, including in the U.S., with submissions targeted for H1 2027, and H2 2027, respectively.
Multi-Abkine is a dual antibody-cytokine fusion platform that integrates a PD-1-바카라ing immune checkpoint inhibitor with a second antibody directed against a different 바카라, depending on the specific pipeline, in combination with an interlukin-2 variant (IL-2v), an immune cell-activating cytokine.
Additionally, three poster abstracts by Y-바카라 on its Multi-AbKine have been accepted for presentation at the 2026 American Association for Cancer Research (AACR 2026), scheduled to be held in San Diego, USA, in mid-April. At AACR 2026, Y-바카라 plans to present data on cytokine variants optimized for the Multi-AbKine platform through its proprietary screening process, together with preclinical findings evaluating the immunomodulatory effects of AR170 and AR166 on antitumor immune cells, as well as their efficacy and safety profiles in animal models.
“The CDMO agreement with WuXi XDC marks the completion of final candidate selection for each of our proprietary R&D pipelines and signifies our transition into the preparatory phase for full-scale clinical development in global markets, including the United States. Both AR170 and AR166 have demonstrated superior efficacy and safety profiles compared with competing treatments and have shown excellent antitumor activity in animal models exhibiting resistance to PD-1 inhibitors. We plan to present these data at AACR 2026 in April,” a Y-Biologics official said.